The administration of medicines to children and young people (CYP) poses a challenge to many parents and healthcare professionals; this is linked to the limited information available for age-appropriate oral formulations.

Download our poster: 'Creating Acceptable Tablets (CAT) - A feasibility study to assess the swallow ability and acceptability of different sized placebo tablets in children and young people: an interim analysis'.

The objective of the study is to evaluate the overall risk on the process transferability of a poorly flowing blend between two (2) - 10 cu.ft V blenders manufactured by different vendors.

Download our poster entitled, 'Evaluation of Process Transferability of Poorly Flowing Blend Between the Blenders Manufactured by Different Vendors.'

Development of an MR formulation of Cmp-1 was planned using RapidFACT®: an integrated approach that allows formulation optimization based on human PK data with an adaptive clinical design. Selection of a discriminatory in vitro dissolution test was an important early development activity. 

Request a copy of our poster, 'Development of a Modified Release Tablet Containing an API Prone to Form Changes and Gelling in Aqueous Media.'

Chronic drooling or sialorrhoea is evident in the pediatric population and is particularly prominent in those who suffer from neurological disorders such as cerebral palsy.

Download our poster titled, 'Development and Approval of a Palatable Glycopyrronium Bromide Liquid Formulation for Pediatrics' here.

Download Quotient Sciences' poster, 'Identification and Optimization of Critical Process Parameters of Roller Compacted Capsules From Development to Registration Batches'.

TOP1288 is a non-systemic kinase inhibitor (NSKI) being developed as a treatment for patients with ulcerative colitis. As a novel, locally-acting candidate, TOP1288 has low systemic bioavailability, and therefore a dual-pronged formulation strategy was adopted with rectal and oral formulations being developed.

Download Quotient Sciences' poster, 'Rapid Development and Clinical Assessment of New Rectal and Oral Formulations for Ulcerative Colitis Using Real-Time Adaptive GMP Manufacturing and Supply'.

The results of this study demonstrate that CMS delivered as ColistAir has a comparable safety profile to the comparator products and is well tolerated in healthy volunteers. 

Download our scientific poster highlighting the results of a study demonstrating that CMS delivered as ColistAir has a comparable safety profile to the comparator products and is well tolerated in healthy volunteers.

PUR1900 is an iSPERSE™ formulation incorporating a large, complex anti-fungal compound that can be administered at high therapeutic dose to the lung while minimizing systemic side effects.

This Phase 1/1b study was conducted to evaluate the safety, tolerability and pharmacokinetics of PUR1900 in healthy volunteers and asthmatics. Request a copy of our poster now.

Download Quotient Sciences', 'How do I quickly develop first-in-human (FIH) dosage forms and avoid CMC delays whilst achieving proof-of-concept (POC)?'.

Our scientific poster includes the following:
 

• Choosing the appropriate dosage form for first-in-human/Phase I trials. 
• Pharmacy preparation or GMP manufacturing? 
• Bridging to robust and scalable Phase II drug products. 
• Flexible and adaptive clinical manufacturing strategies for patient trials. 
• Integrating pharmaceutical sciences and clinical testing. 

The objective of this development program was to design an age-appropriate multi-dose liquid product suitable for the neonate population (up to 28 days old). 

Request a copy of our scientific poster from EUPFI 2019 titled, 'Development of Oral Liquid Products for Neonatal Patients'.